Form 4: IMMUNIC Executive Chairman Granted Over 2.2 Million Stock Appreciation Rights

IMMUNIC, INC. Executive Chairman Duane Nash was granted 2,205,000 Stock Appreciation Rights with an exercise price of $0.77, exercisable from August 1, 2026, subject to certain conditions.

Summary

• Duane Nash, Executive Chairman and Director of IMMUNIC, INC. (IMUX), was granted a total of 2,205,000 Stock Appreciation Rights (SARs) on July 16, 2025.
• The SARs have an exercise price of $0.77 per share and are set to expire on July 16, 2035.
• All granted SARs will become exercisable beginning August 1, 2026.
• The exercisability of 1,260,000 SARs (two tranches of 630,000 each) is contingent upon the exercise of the Issuer's Series A and Series B purchase warrants by their respective holders.
• The exercisability of an additional 630,000 SARs (two tranches of 315,000 each) is contingent upon the Issuer's issuance of Common Stock or pre-funded warrants to subscribers in connection with the second and third tranches of the January 4, 2024 private placement.
• The Issuer intends to settle these SARs for shares of common stock, provided stockholder approval is obtained to amend the 2019 Omnibus Equity Incentive Plan to support share settlement.

Sentiment

Score: 6

Explanation: The grant of Stock Appreciation Rights to a key executive is generally a neutral to slightly positive event, indicating management alignment with shareholder interests. However, the contingent nature of exercisability for a large portion of the SARs introduces some uncertainty.

Positives

• The grant of Stock Appreciation Rights to Executive Chairman Duane Nash aligns management's interests with shareholder value creation, as the SARs gain value only if the company's stock price increases above the $0.77 exercise price.
• The intention to settle SARs in shares, pending stockholder approval, could reduce potential cash outflow for the company compared to cash settlement.

Negatives

• The exercisability of a significant portion of the SARs (1,890,000 out of 2,205,000) is contingent on future events, including the exercise of warrants and the completion of private placement tranches, introducing uncertainty regarding their immediate value realization for the executive.
• Potential future dilution for existing shareholders if the SARs are settled in shares of common stock, pending stockholder approval.

Risks

• The value of the granted Stock Appreciation Rights is subject to the future market price of IMMUNIC, INC. common stock; if the stock price does not rise above the $0.77 exercise price, the SARs may hold no intrinsic value.
• The ability to exercise a substantial portion of the SARs is contingent on external factors, specifically the exercise of Series A and Series B purchase warrants and the successful completion of the second and third tranches of the January 2024 private placement, which may not occur as anticipated.
• The intended share settlement of SARs is contingent on obtaining stockholder approval to amend the 2019 Omnibus Equity Incentive Plan, and failure to obtain this approval could lead to cash settlement, impacting the company's liquidity.

Future Outlook

The exercisability of a significant portion of the granted Stock Appreciation Rights is contingent on future events, including the exercise of the Issuer's Series A and Series B purchase warrants and the successful completion of the second and third tranches of the January 2024 private placement. The Issuer also intends to seek stockholder approval to amend its 2019 Omnibus Equity Incentive Plan to allow for share settlement of these SARs.

Management Comments

• "It is the intention of the Issuer that these SARs will be settled for shares of the Issuer's common stock, par value $0.0001 per share ('Common Stock') provided the Issuer obtains stockholder approval to amend the Issuer's 2019 Omnibus Equity Incentive Plan, as amended, to provide for a sufficient number of shares of Common Stock to support the settlement of the SARs in shares of Common Stock."

Industry Context

This Form 4 filing details an executive compensation event, specifically the grant of Stock Appreciation Rights, which is a common practice in the biotechnology and pharmaceutical industries to incentivize management and align their interests with long-term shareholder value. Such grants are typically part of a broader compensation strategy aimed at retaining key talent and rewarding performance in a highly competitive sector.

Corporate Governance

Related Party Transactions

• The grant of 2,205,000 Stock Appreciation Rights to Duane Nash, an Executive Chairman and Director of IMMUNIC, INC., constitutes a related party transaction as it involves compensation from the company to a key management personnel.

Stakeholder Impact

• Shareholders: Potential for future dilution if the Stock Appreciation Rights are settled in shares of common stock, contingent on stockholder approval. However, the grant also aligns management's incentives with shareholder value creation.
• Management (Duane Nash): Receives significant equity-linked compensation that incentivizes an increase in the company's stock price above $0.77. The exercisability is tied to future corporate actions and market conditions.

Next Steps

• Obtain stockholder approval to amend the Issuer's 2019 Omnibus Equity Incentive Plan to allow for share settlement of Stock Appreciation Rights.
• Exercise of the Issuer's Series A and Series B purchase warrants by their respective holders.
• Issuance of Common Stock or pre-funded warrants in connection with the second and third tranches of the January 2024 private placement.

Key Dates

Keywords

IMMUNIC INC, IMUX, Duane Nash, Stock Appreciation Rights, SARs, Executive Compensation, SEC Form 4, Insider Transaction, Equity Incentive Plan, Private Placement, Warrants